Founded in 2014 in Zhangjiagang, Suzhou, Suzhou Biosynthetica manufactures nucleoside and nucleotide building blocks for mRNA and oligonucleotide therapeutics, including modified nucleosides such as N1-methylpseudouridine, pseudouridine, 2'-fluoro-2'-deoxyadenosine, and 2'-deoxy-2'-fluoroguanosine, alongside beta-nicotinamide mononucleotide (NMN precursor chemistry), cytidine, uridine, and L-histidine. Built on a green, low-carbon biomanufacturing process the company describes as converting CO2 to sugar and then to product, Biosynthetica has received multiple Jiangsu provincial and Zhangjiagang municipal high-tech and talent recognitions, filed 21 patents (4 granted), and offers CRO services to customers across North America, Europe, Asia, the Middle East, and Africa.
No comments available.
Leave your rating & comment